Intercept Pharmaceuticals increases deal size, prices IPO at $15, at high end of the range


Shutterstock photo

Intercept Pharmaceuticals, which is developing novel synthetic therapeutics for chronic liver diseases, raised $75 million by offering 5.0 million shares at $15, at high end of the range of $13 to $15. The company was able to raise an additional $11 million by offering an additional 700,000 shares. Intercept Pharmaceuticals plans to list on the NASDAQ under the symbol ICPT. BofA Merrill Lynch acted as the lead bookrunner on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines IPOs
Referenced Stocks: ICPT

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by